-
MSD’s Welireg Gains FDA Approval for Advanced Renal Cell Carcinoma
•
The US Food and Drug Administration (FDA) has granted an indication extension approval for Merck, Sharp & Dohme’s (MSD; NYSE: MRK) oral drug Welireg (belzutifan), expanding its use as a therapy for advanced renal cell carcinoma (RCC) in adults who have previously received a PD-1/L1 inhibitor and a VEGF tyrosine…
-
Bayer Partners with ClearNote Health to Explore Prostate Cancer Treatment Response
•
German multinational pharmaceutical company Bayer (ETR: BAYN) has partnered with U.S. diagnostics firm ClearNote Health to delve into the study of treatment response and resistance in metastatic hormone-sensitive prostate cancer. The collaborative project will leverage ClearNote’s epigenomic platform, which employs machine learning algorithms to analyze patient blood samples, monitor DNA-based…
-
3D Medicines Initiates Phase III Trial for Envafolimab in NSCLC Patient
•
3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the enrollment of the first patient in a Phase III clinical study for its PD-L1 monoclonal antibody (mAb), envafolimab. The randomized, controlled, double-blinded, multi-center trial will evaluate envafolimab in combination with chemotherapy as a neoadjuvant/adjuvant therapy for patients with resectable…
-
BMS Partners with Terray Therapeutics for AI-Driven Drug Discovery
•
Bristol Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with U.S.-based Terray Therapeutics to discover and develop multiple small-molecule drugs in undisclosed therapeutic areas. Under the terms of the agreement, BMS will receive development and commercialization rights, and in return, will provide Terray with upfront payments and potential…
-
Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), and Suzhou-based Medilink Therapeutics have jointly announced the licensing of their co-developed antibody-drug conjugate (ADC), HBM9033 (YL215), to Pfizer Inc.’s (NYSE: PFE) unit Seagen Inc. (NASDAQ: SGEN). According to the agreement, Seagen will secure global clinical development and commercialization rights…
-
VectorBuilder Partners with Sino Biological to Boost Global Biological Reagents Market
•
VectorBuilder, a genetic engineering specialist based in Guangzhou and nurtured by the state-owned Guangzhou Industrial Investment and Capital Operation Holding Group, has entered into a partnership with Sino Biological, Inc. (SHE: 301047), a global leader in the provision of mammalian cell-based recombinant proteins, antibodies, and related contract research services. This…
-
CATUG Biotechnology Partners with Carcell Biopharma to Advance Nucleic Acid Drug Development
•
CATUG Biotechnology (Suzhou) Co., Ltd, a Chinese biotechnology company, has entered into a partnership with domestic firm Carcell Biopharma, a developer of medical technology service platforms. The collaboration will focus on technical cooperation in the global development of Lipid Nanoparticle (LNP) delivered mRNA and other nucleic acid drugs, aiming to…
-
Sino Biopharmaceutical Submits Market Approval Application for Recombinant Coagulation Factor VIIa
•
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the submission of a market approval application for its in-house developed recombinant human coagulation factor VIIa. The application has been accepted for review by China’s National Medical Products Administration (NMPA). The drug candidate is being developed…
